Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
ProMIS Neurosciences Inc. - Common Shares
(NQ:
PMN
)
2.230
+0.240 (+12.06%)
Streaming Delayed Price
Updated: 3:57 PM EDT, Jul 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
51,679
Open
1.990
Bid (Size)
2.010 (3)
Ask (Size)
2.230 (1)
Prev. Close
1.990
Today's Range
1.930 - 2.330
52wk Range
0.9500 - 8.950
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024
May 15, 2024
PMN stock results show that ProMIS Neurosciences beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14, 2024
Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Performance
YTD
+60.48%
+60.48%
1 Month
+30.41%
+30.41%
3 Month
-7.08%
-7.08%
6 Month
+51.70%
+51.70%
1 Year
-34.41%
-34.41%
More News
Read More
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
April 30, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Via
Benzinga
Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings
April 15, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
April 09, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
April 04, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023
April 01, 2024
Via
InvestorPlace
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
April 01, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
March 11, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
February 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
January 22, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
January 19, 2024
Via
Benzinga
ProMIS Neurosciences Issues Letter to Shareholders
January 08, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences, Inc. Announces Leadership Transition
January 03, 2024
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Publication on Novel Target for ALS
December 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease
November 20, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
November 14, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing
September 08, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
October 03, 2023
Via
Benzinga
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
ProMIS Neurosciences Inc.
Via
GlobeNewswire
Crude Oil Falls; Dick's Sporting Goods Earnings Miss Views
August 22, 2023
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
Fossil Fuels
US Equities
Why ProMIS Neurosciences Shares Are Trading Higher By 33%; Here Are 20 Stocks Moving Premarket
August 22, 2023
Via
Benzinga
Why Macy's Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 22, 2023
Via
Benzinga
Exposures
Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
August 22, 2023
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.